Exploring the Differences in Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients
- PMID: 36106266
- PMCID: PMC9441775
- DOI: 10.7759/cureus.27727
Exploring the Differences in Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients
Abstract
Pneumocystis pneumonia (PCP) is one of the most common opportunistic infections worldwide that affects the lung. Pneumocystis leads to pneumonia, caused by Pneumocystis jirovecii, formerly known as Pneumocystis carinii. In recent decades, PCP has been a major health problem for human immunodeficiency virus (HIV) patients and is responsible for most of mortality and morbidity. However, the increasing number of immunosuppressive-related diseases has led to outbreaks in other patient populations, raising the concern for PCP as it becomes a major concern among those patients. These changes led to marked changes in the prevalence and mortality rates of PCP. Huge variations in those parameters among HIV and non-HIV patients have been seen also. Historically, the diagnosis was made by staining and direct visualization of the organism within the bronchoalveolar lavage (BAL) fluid. The diagnosis is now made by microscopic examination and a real-time polymerase chain reaction (PCR) of BAL. Serum (1,3)-β-D-glucan, which is a component of the Pneumocystis jirovecii cell wall that distinguishes it from other fungi, has become an important diagnostic tool. Early diagnosis and treatment play a vital role in the patient's survival and in the infection outcome; hence, empirical PCP therapy should be started immediately when the infection is suspected without waiting for the results of the diagnostic test. Steroids play an important role in the treatment of HIV patients, especially patients who present with hypoxia and respiratory failure. Prophylaxis is very effective and should be given to all patients at high risk of PCP. Antiretroviral therapy (ART) should be started as soon as possible in newly diagnosed HIV-infected patients with PCP, and the immune status of immunocompromised patients with PCP should be improved by temporarily withholding immunosuppressive drugs or reducing their doses.
Keywords: epidemiology; hiv; non-hiv; outcome; pneumocystis jirovecii pneumonia; prophylaxis; treatment.
Copyright © 2022, Nasr et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Recent advances in the diagnosis and management of Pneumocystis pneumonia. Tasaka S. https://doi.org/10.4046/trd.2020.0015. Tuberc Respir Dis (Seoul) 2020;83:132–140. - PMC - PubMed
-
- Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review. Sokulska M, Kicia M, Wesołowska M, Hendrich AB. https://doi.org/10.1007/s00436-015-4678-6. Parasitol Res. 2015;114:3577–3585. - PMC - PubMed
-
- Trends in the epidemiology and outcomes of Pneumocystis pneumonia among human immunodeficiency virus (HIV) hospitalizations. Elango K, Mudgal M, Murthi S, et al. https://doi.org/10.3390/ijerph19052768 Int J Environ Res Public Health. 2022;19 - PMC - PubMed
-
- Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Salzer HJ, Schäfer G, Hoenigl M, et al. https://doi.org/10.1159/000487713. Respiration. 2018;96:52–65. - PubMed
Publication types
LinkOut - more resources
Full Text Sources